UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies

Investigational new drugs, 2022-06, Vol.40 (3), p.586-595

2022

Volltextzugriff (PDF)

The Role of the Gut Microbiome in Pediatric Obesity and Bariatric Surgery

International journal of molecular sciences, 2022-12, Vol.23 (23), p.15421

2022

Volltextzugriff (PDF)

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)

Blood, 2023-11, Vol.142 (Supplement 1), p.3095-3095

2023

Volltextzugriff (PDF)

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Blood, 2022-11, Vol.140 (Supplement 1), p.12728-12730

2022

Volltextzugriff (PDF)

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-12, Vol.12 (24), p.7406-7413

2006

Volltextzugriff (PDF)

Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Blood, 2021-11, Vol.138 (Supplement 1), p.3847-3847

2021

Volltextzugriff (PDF)

Abstract CT056: A Phase Ia/IIa trial of AVID100, an anti-EGFR antibody-drug conjugate

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT056-CT056

2019

Volltextzugriff (PDF)

Duration and Consistency of Historical Selection are Correlated with Adaptive Trait Evolution in the Streamside Salamander, Ambystoma barbouri

Evolution, 2009-10, Vol.63 (10), p.2636-2647

2009

Volltextzugriff (PDF)

AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3587-3587

2020

Volltextzugriff (PDF)

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Blood, 2020-11, Vol.136 (Supplement 1), p.6-8

2020

Volltextzugriff (PDF)

Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.A088-A088

2019

Volltextzugriff (PDF)

Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15721-e15721

2016

Volltextzugriff (PDF)

ACTR-64. PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi14-vi14

2017

Volltextzugriff (PDF)

Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report

Journal of neuro-oncology, 2011-01, Vol.101 (2), p.307-310

2011

Volltextzugriff (PDF)

Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody—treated liver transplant patients

Hepatology (Baltimore, Md.), 1992-05, Vol.15 (5), p.757-766

1992

Volltextzugriff (PDF)

A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15270-e15270

2015

Volltextzugriff (PDF)

P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients

Journal for immunotherapy of cancer, 2020-04, Vol.8 (Suppl 1), p.A6-A7

2020

Volltextzugriff (PDF)

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trial

Cancer chemotherapy and pharmacology, 2007-07, Vol.60 (2), p.295-303

2007

Volltextzugriff (PDF)

An Interactive Computer Kiosk Module for the Treatment of Recurrent Uncomplicated Cystitis in Women

Journal of general internal medicine : JGIM, 2006-11, Vol.21 (11), p.1156-1159

2006

Volltextzugriff (PDF)

Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

Clinical pharmacology and therapeutics, 1984-05, Vol.35 (5), p.722-727

1984

Volltextzugriff (PDF)

Pastoral Elements in John Bull's Other Island

Modern drama, 1995-12, Vol.38 (4), p.520-524

Nadler, Paul

1995

Volltextzugriff (PDF)

Liberty Censored: Black Living Newspapers of the Federal Theatre Project

African American review, 1995-12, Vol.29 (4), p.615-622

Nadler, Paul

1995

Volltextzugriff (PDF)

THE SELF-DELUSION IN SOCIAL LENDING

Business and society review (1974), 1972-07, Vol.1 (2), p.34

Nadler, Paul

1972

Volltextzugriff (PDF)

1 – 25 von 1.657

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(186)
Mit Volltextzugriff
(1.469)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.653)
Japanisch
(12)
Deutsch
(3)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The American Banker
(1.184)
The Secured Lender
(116)
Commercial Lending Review
(57)
Banking
(51)
The Journal Of Finance
(11)
The Bankers Magazine
(10)
Harvard Business Review
(9)
Journal Of The National Comprehensive Cancer Network
(9)
Blood
(5)
Canadian Banker
(5)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies

The Role of the Gut Microbiome in Pediatric Obesity and Bariatric Surgery

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Abstract CT056: A Phase Ia/IIa trial of AVID100, an anti-EGFR antibody-drug conjugate

Duration and Consistency of Historical Selection are Correlated with Adaptive Trait Evolution in the Streamside Salamander, Ambystoma barbouri

AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors

Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX

ACTR-64. PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report

Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody—treated liver transplant patients

A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX

P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trial

An Interactive Computer Kiosk Module for the Treatment of Recurrent Uncomplicated Cystitis in Women

A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis

Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

Pastoral Elements in John Bull's Other Island

Liberty Censored: Black Living Newspapers of the Federal Theatre Project

THE SELF-DELUSION IN SOCIAL LENDING

Suchergebnisse filtern